finally, blueberg. this is the least compelling daily chart of the three. recent surge over its 50 day moving average they got hammered, plummeting $8.41, nearly 10% after investors reacted negatively to comments and a general positive piece of research. it suggested there could be a potential delay in one of the lead drug candidates, treatment for a rare blood disorder that allows patients who would otherwise need frequent blood transfusions to get by just fine without them. given that people are told to buy blueberg $204 price target on an $80 stock, lang thinks today's pull-back is a real overreaction. first, the indicator, again, we have got, this is this one, got that bullish crossover we like to see where the black line crossed over the red one. okay? got that. pretty reliable signal. the momentum indicator like the relative strength index, looked very strong. i was concerned about this. bob tells me it's okay. and the money flow oscillator which just turned positive, down at the bottom here, it suggests the big boys are just getting started. it's not

blueberg has gone from $200 -- well went from $200 down to $53. downgrades today. i know we'll talk about it earlier. but this stock has $900 million in cash. it is absolutely being dismantled because of the data out of ash. they need more time. we believe it does work out for the sickle cell drug. a lot of pharma needs to bolt on product and this is an opportunity to do so. you could buy it for one of four -- the value of one of four of their essential franchises if you will. >> look at that. absolutely slaughtered today in trade. what about you, guy? >> beaten down stocks. we are trading at 15-year lows. trading lower than we saw in the '09 low i believe. and it is basically saying they will never sell another hot rolled steel item in it their lifetime. which i know is false. i'm not trying to pick a bottom in steel because i think there is pain on the down side. but with the billionon dollar market cap, any incremental news will send the stock higher. for someone to take a flier on the steel industry that is beaten down to own the best brend, u.s. steel is the b

i'm joined now by the ceo of blueberg.ot of data coming out and some people call it mixed. this is in your gene therapy that seeks to cure sickle cell. is thinking about a cure the right way to think about it given the new data? >> i think it is. when you think about gene therapy and promise we bring to patients, you can put it in that category and it is early. and so you mentioned the world mixed. if you look from a patient perspective and you look at the data and ability to take the patients from a situation where they have a shortened life span to potentially having a normal life span, i'm not sure i would call those results mixed. >> we're talking about -- let's go for sickle cell first. tiny numbers of patients. a handful of patients. one of them is doing incredibly well. transfusion free. what can you tell us about the data? >> we're studying and learning. that first patient, that's a 13-year-old boy who was dependent on transfusions to stay alive. and now is free of some of the symptoms or most of the symptoms if no